With the progression of CT technology， CT coronary angiography (CTCA) is frequently used as a noninvasive diagnostic tool for CHD. But the high radiation doses prohibit the use of this test as a screening tool for asymptomatic patients. Cardiac ultrasound technology has developed quickly. We have some new methods such as Myocardial Contrast Echocardiography. Do you think Cardiac ultrasound technology will become a main tool to screen CHD in the future?
随着冠状动脉CT技术的发展，它的应用已经非常广泛，然而大剂量的辐射限制了它作为冠心病筛查的常规手段。心脏超声技术近年发展迅速，出现了心肌造影超声心动图等新的检测技术，您认为超声技术在未来有可能成为冠心病筛查的重要手段吗？ 


A recent trial have demonstrated that for infarct size by contrast-enhanced cardiac magnetic resonance imaging Is a Stronger Predictor for STEMI than EF and ESVI. How do you evaluate this tool used in CHD?
一项最近的研究显示对于STEMI患者，利用心脏磁共振成像测量的梗死面积是优于EF或ESVI的预测因子。关于这项技术在冠心病领域的应用，您有什么样的看法呢？


You have published some articles about mitral regurgitation. Functional mitral regurgitation (MR) is a frequent complication of systolic heart failure. What is the most effective tool to make a diagnosis of functional MR? and what is the clinical significance of functional MR in HF patients?
您已经发表了多篇关于二尖瓣返流的文章，功能性二尖瓣返流在心衰患者中很常见。功能性二尖瓣返流最有效的诊断手段是什么？心衰患者功能性二尖瓣返流有什么临床意义？

专家介绍：
Luc A Pierard， MD PhD FESC FACC
比利时Liège大学医院心脏科主任，主要研究方向为心血管影像学。为ESC的教材撰稿人之一，在2008 ESC年会最为关键的Highlight部分总结了本届大会的心血管影像学进展。